SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

EloraTZP

LLY·ELI LILLY & Co
MIXED
Drug Impact Rating4/10
Trial phase
Phase 2b completed; Phase 3 registered but not yet recruiting
Time to market
With Phase 3 enrollment beginning in late 2026 and primary completion estimated around October 2029, followed by regulatory filing and review, a potential FDA approval is likely 4-6 years out, barring accelerated development.
Why 4/10
No hard dated binary catalyst (PDUFA, pivotal readout, AdComm) is scheduled within the next ~12 months; the Phase 2b data has already been released, and Phase 3 topline results are not expected until ~2029. At a mega-cap company with a deep pipeline (tirzepatide, retatrutide, orforglipron, donanemab, etc.), EloraTZP is one of many value drivers, limiting the stock-specific impact of any single newsflow.
Actionable Insight MIXED

Phase 3 trials AMPLIFY-1 (NCT07881432, obesity without diabetes, ~2,115 patients) and AMPLIFY-2 (NCT07881458, obesity/overweight with type 2 diabetes) are expected to begin enrollment around December 2026, but topline results are not expected until late 2029 at the earliest -- no near-term binary catalyst. Watch for the optimized co-formulation details and any updated dose-escalation regimens that could improve the tolerability profile before the Phase 3 program fully launches.

Price Chart

Loading chart...

Executive Summary

EloraTZP is Eli Lilly's investigational once-weekly combination of eloralintide (a selective amylin receptor agonist) and tirzepatide (the dual GIP/GLP-1 receptor agonist already approved as Zepbound and Mounjaro). Positive Phase 2b results presented at EASD 2026 showed up to 23.3% average weight loss at 48 weeks in adults with obesity and type 2 diabetes, significantly beating tirzepatide alone (14.8%). However, treatment discontinuation due to adverse events reached 10.8%-27% across EloraTZP arms versus 2.9% for tirzepatide, a notable tolerability gap. Lilly registered two Phase 3 trials (AMPLIFY-1 and AMPLIFY-2) in October 2026, with enrollment expected to begin in Q4 2026 and primary completion estimated for October 2029. For a mega-cap like Lilly, EloraTZP is one of several high-profile obesity-pipeline assets alongside retatrutide and orforglipron, meaning a single drug moves the stock only modestly.

How It Works

EloraTZP is a combination therapy that targets three hormone-signaling pathways at once. Tirzepatide (the active ingredient in Zepbound/Mounjaro) activates two gut-hormone receptors called GIP and GLP-1 to reduce appetite and improve blood sugar control. Eloralintide activates a third pathway called amylin, a pancreatic hormone that also signals fullness. By combining both into one weekly injection, the drug aims to produce greater weight loss than tirzepatide alone.

Trial Status

A 48-week Phase 2b trial in 367 adults with obesity or overweight and type 2 diabetes met its primary and secondary endpoints, with results presented at EASD 2026 on September 30, 2026. Two Phase 3 trials (AMPLIFY-1, NCT07881432, for obesity without diabetes, and AMPLIFY-2, NCT07881458, for obesity/overweight with type 2 diabetes) were registered on ClinicalTrials.gov in October 2026. Both are listed as not yet recruiting, with estimated enrollment start of December 1, 2026 for AMPLIFY-1 and primary completion by October 2029.

The Two-Sided Case

▲ Bull Case4
Phase 2b data showed EloraTZP produced up to 23.3% average weight loss at 48 weeks, far exceeding tirzepatide 15 mg alone (14.8%), a highly competitive profile in the obesity market.
A1C reduction of up to 2.9% (vs 2.4% for tirzepatide) demonstrates meaningful additive glycemic benefit for patients with type 2 diabetes.
Lilly is rapidly advancing to Phase 3 with two registered trials (AMPLIFY-1 and AMPLIFY-2), signaling confidence in the data and the potential for a co-formulated product.
The triple-pathway mechanism (amylin + GIP + GLP-1) could differentiate EloraTZP from single-mechanism competitors and from Novo Nordisk's amycretin/zenagamtide (GLP-1/amylin only).
▼ Bear Case5
Tolerability is a significant concern: discontinuation due to adverse events ranged from 10.8% to 27% across EloraTZP arms versus just 2.9% for tirzepatide alone, potentially limiting real-world adoption.
The Phase 2b data have not yet appeared in a peer-reviewed journal, and the topline results may be less compelling when full data are scrutinized.
Phase 3 trials will not read out until approximately October 2029, leaving years for competitors (Novo Nordisk's amycretin/zenagamtide and other amylin combos) to advance or capture market share.
Lilly already markets tirzepatide (Zepbound/Mounjaro) and has retatrutide in Phase 3; EloraTZP could cannibalize the company's own approved products rather than add entirely new revenue.
The drug currently requires separate injections of two molecules; a stable co-formulation has not yet been validated in Phase 3.

Upcoming Catalysts

  • Phase 3 enrollment initiation for AMPLIFY-1 (estimated December 2026) and AMPLIFY-2 (estimated November 2026)
  • Any presentation of additional Phase 2b subgroup or mechanistic data at medical congresses
  • Details on the co-formulation development and dose-escalation optimization for Phase 3

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ELI LILLY & Co 8-K LLY ·Originating report

Sources · 10

Hover a chip for the title
1 investor.lilly.com2 prnewswire.com3 biospace.com4 reuters.com5 hcplive.com6 clinicaltrials.gov7 clinicaltrials.gov8 medicaldaily.com9 fiercebiotech.com10 drugtopics.com